Profile Response Detail

Molecular Profile KRAS G12D
Therapy Selumetinib
Indication/Tumor Type lung adenocarcinoma
Response Type decreased response
Create By c-xyi
Update By c-xyi

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12D lung adenocarcinoma decreased response Selumetinib Preclinical Actionable In a preclinical study, the treatment of a mouse model lung adenocarcinoma harboring the KRAS G12D mutant with selumetinib, a MEK inhibitor, resulted in modest tumor regression (PMID: 19029981). 19029981
PubMed Id Reference Title Details
(19029981) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Full reference...